BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, January 5, 2026
Home » Topics » Financings, BioWorld MedTech

Financings, BioWorld MedTech
Financings, BioWorld MedTech RSS Feed RSS

Financings for Jan. 2, 2026

Jan. 2, 2026
Med-tech firms raising money in public or private financings, including: INBS.
Read More
Shenzhen Edge Medical Co. Ltd.’s Multi-Port Endoscopic Surgical Robot

Surgical robotic maker Shenzhen Edge announces $154M HKEX IPO

Dec. 31, 2025
By Tamra Sami
Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China.
Read More
IPO line graph
Year in review

Med-tech IPOs shoot for the stars in 2025

Dec. 31, 2025
By Annette Boyle
IPOs top the list of the big stories in 2025 in med tech. Thirty med-tech companies went public, raising nearly $12 billion, two orders of magnitude more than in 2023 and almost 20 times more than raised in 2024.
Read More

Financings for Dec. 31, 2025

Dec. 31, 2025
Med-tech firms raising money in public or private financings, including: Biobeat Technologies, Positron, Profound Medical.
Read More

Financings for Dec. 30, 2025

Dec. 30, 2025
Med-tech firms raising money in public or private financings, including: Glucotrack, Pathocare.
Read More
Diamond cut, ombre EU flag
The year in review

2025 leaves a few bright spots in Europe’s med-tech sector

Dec. 29, 2025
By Shani Alexander
The level of investment in Europe’s med-tech sector in 2025 did not materialize as many had hoped at the beginning of the year. Reciprocal tariffs introduced by the U.S. government created an uncertain macroeconomic environment, curtailing dealmaking and slowing financing activity. Nevertheless, amid uncertainty, there were some bright spots as medical devices remain essential, and investors know how to navigate market cycles.
Read More
Livsmed Artisential

Laparoscopic instruments maker Livsmed tops 2025 Kosdaq IPOs

Dec. 29, 2025
By Marian (YoonJee) Chu
Livsmed Inc. closed the year’s biggest Kosdaq IPO with a ₩135.85 billion (US$94 million) haul Dec. 24. Livsmed specializes in the development of hand-held multi-joint laparoscopic surgical instruments for minimally invasive procedures.
Read More

Financings for Dec. 29, 2025

Dec. 29, 2025
Med-tech firms raising money in public or private financings, including: Profound Medical.
Read More

Financings for Dec. 24, 2025

Dec. 24, 2025
Med-tech firms raising money in public or private financings, including: Nanalysis Scientific, Picard Medical, Sequana Medical.
Read More

Financings for Dec. 23, 2025

Dec. 23, 2025
Med-tech firms raising money in public or private financings, including: Profound Medical.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 252 253 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 2, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing